Chinese Journal of Dermatology ›› 2025, Vol. 58 ›› Issue (1): 72-75.doi: 10.35541/cjd.20240383
• Expert Commentary • Previous Articles Next Articles
Wang Bo1,2,3, Zheng Jie1
Received:
2024-07-17
Revised:
2024-12-11
Online:
2025-01-15
Published:
2025-01-03
Contact:
Zheng Jie
E-mail:jie-zheng2001@126.com
Wang Bo, Zheng Jie. Considerations in the treatment of elderly patients with psoriasis and atopic dermatitis using biologics and small-molecule drugs[J]. Chinese Journal of Dermatology, 2025, 58(1): 72-75.doi:10.35541/cjd.20240383
[1] | Griffiths C, Armstrong AW, Gudjonsson JE, et al. Psoriasis[J]. Lancet, 2021,397(10281):1301⁃1315. doi: 10.1016/S0140⁃6736(20)32549⁃6. |
[2] | Ständer S. Atopic dermatitis[J]. N Engl J Med, 2021,384(12):1136⁃1143. doi: 10.1056/NEJMra2023911. |
[3] | Shen X, Wang B, Li K, et al. MicroRNA signatures in diagnosis and prognosis of cutaneous T⁃cell lymphoma[J]. J Invest Dermatol, 2018,138(9):2024⁃2032. doi: 10.1016/j.jid.2018.03. 1500. |
[4] | Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents[J]. J Am Acad Dermatol, 2019,80(1):27⁃40. doi: 10.1016/j.jaad.2018.06.057. |
[5] | Megna M, Potestio L, Fabbrocini G, et al. Treating psoriasis in the elderly: biologics and small molecules[J]. Expert Opin Biol Ther, 2022,22(12):1503⁃1520. doi: 10.1080/14712598.2022. 2089020. |
[6] | Bozon A, Nancey S, Serrero M, et al. Risk of infection in elderly patients with inflammatory bowel disease under biologics: a prospective, multicenter, observational, one⁃year follow⁃up comparative study[J]. Clin Res Hepatol Gastroenterol, 2023,47(5):102107. doi: 10.1016/j.clinre.2023.102107. |
[7] | Di Caprio R, Caiazzo G, Cacciapuoti S, et al. Safety concerns with current treatments for psoriasis in the elderly[J]. Expert Opin Drug Saf, 2020,19(4):523⁃531. doi: 10.1080/14740338. 2020.1728253. |
[8] | Ebina K. Drug efficacy and safety of biologics and Janus kinase inhibitors in elderly patients with rheumatoid arthritis[J]. Mod Rheumatol, 2022,32(2):256⁃262. doi: 10.1093/mr/roab003. |
[9] | Migliore A, Bizzi E, Laganà B, et al. The safety of anti⁃TNF agents in the elderly[J]. Int J Immunopathol Pharmacol, 2009,22(2):415⁃426. doi: 10.1177/039463200902200218. |
[10] | Rodríguez⁃Cerdeira C, González⁃Cespón JL, Martínez⁃Herrera E, et al. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin⁃17 inhibitors and their practical management[J]. Ital J Dermatol Venerol, 2021,156(5):545⁃557. doi: 10.23736/S2784⁃8671.20.06580⁃3. |
[11] | Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti⁃interleukin⁃23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase Ⅲ, double⁃blinded, placebo⁃ and active comparator⁃controlled VOYAGE 1 trial[J]. J Am Acad Dermatol, 2017,76(3):405⁃417. doi: 10.1016/j.jaad.2016.11.041. |
[12] | Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti⁃interleukin⁃23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase Ⅲ, double⁃blind, placebo⁃ and active comparator⁃controlled VOYAGE 2 trial[J]. J Am Acad Dermatol, 2017,76(3):418⁃431. doi: 10.1016/j.jaad.2016. 11.042. |
[13] | Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials[J]. Lancet, 2017,390(10091):276⁃288. doi: 10. 1016/S0140⁃6736(17)31279⁃5. |
[14] | Wollenberg A, Blauvelt A, Guttman⁃Yassky E, et al. Tralokinumab for moderate⁃to⁃severe atopic dermatitis: results from two 52⁃week, randomized, double⁃blind, multicentre, placebo⁃controlled phase Ⅲ trials (ECZTRA 1 and ECZTRA 2)[J]. Br J Dermatol, 2021,184(3):437⁃449. doi: 10.1111/bjd. 19574. |
[15] | Boesjes CM, van der Gang LF, Bakker DS, et al. Dupilumab⁃associated lymphoid reactions in patients with atopic dermatitis[J]. JAMA Dermatol, 2023,159(11):1240⁃1247. doi: 10.1001/jamadermatol.2023.3849. |
[16] | Hasan I, Parsons L, Duran S, et al. Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study[J]. J Am Acad Dermatol, 2024,91(2):255⁃258. doi: 10.1016/j.jaad.2024.03.039. |
[17] | SCORE2⁃OP working group and ESC Cardiovascular risk collaboration. SCORE2⁃OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions[J]. Eur Heart J, 2021,42(25):2455⁃2467. doi: 10.1093/eurheartj/ehab312. |
[18] | Tashiro T, Sawada Y. Psoriasis and systemic Inflammatory Disorders[J]. Int J Mol Sci, 2022,23(8):4457. doi: 10.3390/ijms23084457. |
[19] | Nguyen T, Wu JJ. Relationship between tumor necrosis factor⁃α inhibitors and cardiovascular disease in psoriasis: a review[J]. Perm J, 2014,18(1):49⁃54. doi: 10.7812/TPP/13⁃092. |
[20] | Akash M, Rehman K, Liaqat A. Tumor necrosis factor⁃alpha: role in development of insulin resistance and pathogenesis of type 2 diabetes mellitus[J]. J Cell Biochem, 2018,119(1):105⁃110. doi: 10.1002/jcb.26174. |
[21] | Rosset F, Mastorino L, Dapavo P, et al. Impact of comorbidities in elderly and frail patients and response to biological therapy in psoriasis[J]. Exp Dermatol, 2023,32(7):1162⁃1164. doi: 10. 1111/exd.14822. |
[22] | Noda S, Suárez⁃Fariñas M, Ungar B, et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization[J]. J Allergy Clin Immunol, 2015,136(5):1254⁃1264. doi: 10.1016/j.jaci.2015. 08.015. |
[23] | Kim J, Ahn K. Atopic dermatitis endotypes: knowledge for personalized medicine[J]. Curr Opin Allergy Clin Immunol, 2022,22(3):153⁃159. doi: 10.1097/ACI.0000000000000820. |
[24] | Blauvelt A, Ladizinski B, Prajapati VH, et al. Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate⁃to⁃severe atopic dermatitis: results from an open⁃label extension of the phase 3, randomized, controlled trial (Heads Up)[J]. J Am Acad Dermatol. 2023,89(3):478⁃485. doi: 10.1016/j.jaad.2023.05.033. |
[25] | Lauffer F, Eyerich K. Eczematized psoriasis ⁃ a frequent but often neglected variant of plaque psoriasis[J]. J Dtsch Dermatol Ges, 2023,21(5):445⁃453. doi: 10.1111/ddg.14991. |
[26] | Borren NZ, Ananthakrishnan AN. Safety of biologic therapy in older patients with immune⁃mediated diseases: a systematic review and meta⁃analysis[J]. Clin Gastroenterol Hepatol, 2019,17(9):1736⁃1743. doi: 10.1016/j.cgh.2018.12.032. |
[27] | Chat VS, Ellebrecht CT, Kingston P, et al. Vaccination recommendations for adults receiving biologics and oral therapies for psoriasis and psoriatic arthritis: Delphi consensus from the medical board of the National Psoriasis Foundation[J]. J Am Acad Dermatol, 2024,90(6):1170⁃1181. doi: 10.1016/j.jaad.2023.12.070. |
[1] | Xu Zhuohong, Hu Yu, Gu Heng. Role of mesenchymal stem cell?derived exosomes in skin diseases [J]. Chinese Journal of Dermatology, 2025, 58(3): 20220881-e20220881. |
[2] | Chen Jiaqi, Zhang Jin, Tang Jun. Relationships between coronavirus disease 2019 and psoriasis [J]. Chinese Journal of Dermatology, 2025, 58(1): 84-88. |
[3] | Chinese Association of Rehabilitation Dermatology, Working Group on Geriatric Dermatology, Combination of Traditional and Western Medicine Dermatology. Expert consensus on the diagnosis, treatment, and rehabilitation of pruritus in the elderly (2025 edition) [J]. Chinese Journal of Dermatology, 2025, 58(1): 1-8. |
[4] | Chinese Association of Rehabilitation Dermatology, Chinese Association of Photodynamic Therapy and Rehabilitation, Photodynamic Therapy Cooperation Center, Chinese Society of Dermatology . Expert consensus on clinical application of aminolevulinic acid photodynamic therapy in non-melanoma skin cancers (2025 edition) [J]. Chinese Journal of Dermatology, 2025, 58(1): 9-19. |
[5] | Liao Caihe, Wang Peiru, Wu Mingshun, Sun Xiaofei, Zhang Guolong, Wang Xiuli. Efficacy and safety of combination therapy with aminolevulinic acid photodynamic therapy in the treatment of facial basal cell carcinoma in the elderly: a retrospective analysis [J]. Chinese Journal of Dermatology, 2025, 58(1): 34-39. |
[6] | Wu Caoying, Yang Yongting, Wang Chun, Shen Yaoyuan, Jia Huihui, Li Tingting, Zhao Juan, Kang Xiaojing. Clinicopathological features and prognostic analysis of melanoma in the elderly [J]. Chinese Journal of Dermatology, 2025, 58(1): 40-46. |
[7] | Jin Lan, Qiu Yun, Wang Weijia, Kang Xiaojing, Ding Yuan. Clinical efficacy and safety of biological agents in the treatment of moderate-to-severe psoriasis in 124 elderly patients: a retrospective analysis [J]. Chinese Journal of Dermatology, 2025, 58(1): 47-52. |
[8] | Yang Zijing, Chen Lihong, Ruan Yeping, Wen Wanting, Zhang Jiayi, Wang Hailun, Pan Meng, Zhao Xiaoqing. Efficacy and safety of dupilumab in the treatment of atopic dermatitis in the elderly [J]. Chinese Journal of Dermatology, 2025, 58(1): 65-69. |
[9] | Ai Fangting, Sun Zijun, Miao Guoying, Yao Chunxia. Role of calcium-sensing receptors in the pathophysiology of skin of the elderly [J]. Chinese Journal of Dermatology, 2025, 58(1): 76-79. |
[10] | Wang Ruixia, Qu Yanlei, Ai Wenjin, Yan Lin, Qu Caijie, Shi Tongxin. A case of nonbullous neutrophilic lupus erythematosus [J]. Chinese Journal of Dermatology, 2024, 57(9): 832-834. |
[11] | Xiang Xi, Zhang Lingyan, Zhong Lin, Gao Yi, Qiu Li. Multimodal ultrasound manifestations of port-wine stains and their application in efficacy assessment of photodynamic therapy [J]. Chinese Journal of Dermatology, 2024, 57(9): 801-806. |
[12] | Zhang Congcong, Shao Xuebao, Zhang Ying, Song Hao, Wang Xiaopo, Zhang Wei, Xu Xiulian, Jiang Yiqun, Zeng Xuesi, Sun Jianfang, Zang Jie, Chen Hao . Expression of common kinase proteins ALK, TRK and ROS1 in Spitz tumors and their associations with clinical and histopathological characteristics of Spitz tumors [J]. Chinese Journal of Dermatology, 2024, 57(9): 807-814. |
[13] | Qiao Jiaxi, Xia Ping, Chen Liuqing. Analysis of dermoscopic and reflectance confocal microscopic features of psoriatic lesions before and after treatment with secukinumab [J]. Chinese Journal of Dermatology, 2024, 57(9): 825-829. |
[14] | Dou Jinfa, Wang Jianbo, Zhang Shuai, Li Jianguo, Liu Hongwei, Zhang Shoumin. Analysis of changes in disease status and their influencing factors in patients with moderate to severe plaque psoriasis receiving biologic therapy during the coronavirus disease 2019 pandemic: a single-center cross-sectional study [J]. Chinese Journal of Dermatology, 2024, 57(8): 739-742. |
[15] | Lin Ziyuan, Pang Tianyi, Wu Jingwen, Jin Hui, . Role of polycyclic aromatic hydrocarbons in the occurrence and development of inflammatory skin diseases [J]. Chinese Journal of Dermatology, 2024, 57(8): 765-769. |
|